A proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by contract development and manufacturing organization (CDMO), Particle Sciences, a Lubrizol LifeSciences company, has been submitted as a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by San-Diego-based Neurelis Inc.   Valtoco, previously referred to in clinical development as ‘NRL-1,’ is the lead product candidate of Neurelis, which worked closely with Particle Sciences on...